Immunogenic and Protective Properties of Recombinant Hemagglutinin of Influenza A (H5N8) Virus
Author:
Rudometova Nadezhda B.1, Fando Anastasia A.1, Kisakova Lyubov A.1, Kisakov Denis N.1, Borgoyakova Mariya B.1ORCID, Litvinova Victoria R.1, Yakovlev Vladimir A.1, Tigeeva Elena V.1, Vahitov Danil I.1, Sharabrin Sergey V.1, Shcherbakov Dmitriy N.1ORCID, Evseenko Veronika I.2, Ivanova Ksenia I.1ORCID, Gudymo Andrei S.1ORCID, Ilyicheva Tatiana N.1ORCID, Marchenko Vasiliy Yu.1ORCID, Ilyichev Alexander A.1, Rudometov Andrey P.1, Karpenko Larisa I.1
Affiliation:
1. Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector», Rospotrebnadzor, Koltsovo 630559, Novosibirsk Region, Russia 2. Institute of Solid State Chemistry and Mechanochemistry, Siberian Branch of Russian Academy of Sciences, Novosibirsk 630090, Novosibirsk Region, Russia
Abstract
In this study, we characterized recombinant hemagglutinin (HA) of influenza A (H5N8) virus produced in Chinese hamster ovary cells (CHO-K1s). Immunochemical analysis showed that the recombinant hemagglutinin was recognized by the serum of ferrets infected with influenza A (H5N8) virus, indicating that its antigenic properties were retained. Two groups of Balb/c mice were immunized with intramuscular injection of recombinant hemagglutinin or propiolactone inactivated A/Astrakhan/3212/2020 (H5N8) influenza virus. The results demonstrated that both immunogens induced a specific antibody response as determined by ELISA. Virus neutralization assay revealed that sera of immunized animals were able to neutralize A/turkey/Stavropol/320-01/2020 (H5N8) influenza virus—the average neutralizing titer was 2560. Immunization with both recombinant HA/H5 hemagglutinin and inactivated virus gave 100% protection against lethal H5N8 virus challenge. This study shows that recombinant HA (H5N8) protein may be a useful antigen candidate for developing subunit vaccines against influenza A (H5N8) virus with suitable immunogenicity and protective efficacy.
Funder
Ministry of Science and Higher Education of the Russian Federation
Subject
Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology
Reference37 articles.
1. Protective Measures for Humans against Avian Influenza A(H5N8) Outbreaks in 22 European Union/European Economic Area Countries and Israel, 2016–2017;Adlhoch;Emerg. Infect. Dis.,2018 2. European Food Safety Authority, European Centre for Disease Prevention and Control, European Union Reference Laboratory for Avian Influenza, Adlhoch, C., Fusaro, A., Gonzales, J.L., Kuiken, T., Marangon, S., Niqueux, É., and Staubach, C. (2022). Avian influenza overview May–September 2021. EFSA J., 20, e07122. 3. Antigua, K.J.C., Choi, W.-S., Baek, Y.H., and Song, M.-S. (2019). The Emergence and Decennary Distribution of Clade 2.3.4.4 HPAI H5Nx. Microorganisms, 7. 4. Alarming situation of emerging H5 and H7 avian influenza and effective control strategies;Shi;Emerg. Microbes Infect.,2023 5. Novel H5N6 reassortants bearing the clade 2.3.4.4b HA gene of H5N8 virus have been detected in poultry and caused multiple human infections in China;Gu;Emerg. Microbes Infect.,2022
|
|